BTG Share PerformanceMore
|52 week high||739.5 12/07/16|
|52 week low||504.0 10/11/15|
|52 week change||136.5 (24.64%)|
|4 week volume||11,238,688 26/09/16|
Latest News« previous» nextMore
14/10/2016 - 14:29 RNS
RNS Number: 6086M BTG PLC 14 October 2016 BTG plc: Notice of Results - Amendment London, UK, 14 October 2016: BTG plc (LSE: BTG), the specialist healthcare company, announces that it will be releasing its unaudited interim results for the six months ended 30 September 2016 (the "Interim Results") on Tuesday 15 November 2016 . For further information con...
14/10/2016 - 12:46 RNS
RNS Number: 6000M BTG PLC 14 October 2016 BTG plc: Notice of Results London, UK, 14 October 2016: BTG plc (LSE: BTG), the specialist healthcare company, announces that it will be releasing its unaudited interim results for the six months ended 30 September 2016 (the "Interim Results") on Thursday 15 November 2016 . For further information contact: BTG FTI...
07/10/2016 - 17:24 Interactive Investor
As a big beneficiary of sterling's plunge and having settled a legal spat in the US, this company's shares have just hit a 12-w...
07/10/2016 - 09:00 StockMarketWire
JP Morgan Cazenove today reaffirms its neutral investment rating on BTG PLC (LON:BTG) and raised its price target to 8...
06/10/2016 - 16:51 StockMarketWire
Utility stocks fell after Prime Minister Theresa May hinted she would increase regulations against the sector to prevent fur...
06/10/2016 - 14:45 StockMarketWire
BTG subsidiary Biocompatibles has reached a settlement with the US government in relation to the Department of Justice'...
06/10/2016 - 14:29 RNS
RNS Number: 9172L BTG PLC 06 October 2016 BTG: settlement of US government investigation into LC Bead London, UK, 6 October 2016: BTG plc (LSE: BTG), the specialist healthcare company, announces that its Biocompatibles, Inc. subsidiary has reached a settlement with the US government in relation to the Department of Justice's investigation of the marketing ...
06/10/2016 - 11:50 StockMarketWire
The FTSE 100 declined 0.3% to 7,013 as tobacco stocks and utility companies continued to drag the blue-chip index lower. Ce...
|Dividend yield||0 %|
Equity Research (BTG)
Growth across all three divisions of BTG’s Interventional Medicine (IM) franchise (oncology, vascular and pulmonology), coupled with currency tailwinds, helped push FY16 revenue towards the upper end...
BTG’s interim results have driven upgrades to our financial forecasts with a small boost to revenues from one-off Zytiga backdated royalties. Our operating expenses are broadly unchanged, but...
BTG’s close period update saw a revision to its FY16 revenue guidance, targeting sales in the lower half of £410-440m (at $1.61/£). This is based on slower-than-expected Varithena sales, despite a...
- 1 of 3
Latest discussion posts More
“Excellent note from Numis 36 pages so won't be posting all but headline below and shows how the broad range of products now being developed, sold and used make the long term ...”▼
“Yahoo Finance 13th Oct 2016 1 pharmaceutical share that could make you a fortune International specialist healthcare firm BTG (LSE: BTG) last week lifted its guidance for ...”▼
“If this guy knew what he was talking about he'd be a millionaire !! I read all the 'tipsters' and trust me if they were right they'd be independent and not a salaried hack ...”▼
Codes & Symbols
|Symbols||BTG, LSE:BTG, BTG.L, BTG:LN, LON:BTG, XLON:BTG|